Related Experiment Videos
Reassessment of the relationship between M-protein decrement and survival in multiple myeloma
1Cancer Research Group, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
The relationship between percentage M-protein decrement and survival is assessed in 134 multiple myeloma patients. The correlation did not achieve statistical significance (P = 0.069). Multivariate analysis using the Cox proportional hazards model, including a number of previously recognised prognostic factors, showed only percentage M-protein decrement, creatinine and haemoglobin to be significantly correlated with survival. However, the R'-statistic for each of these variables was low, indicating that their prognostic power is weak. We conclude that neither the percentage M-protein decrement nor the response derived from it can be used as an accurate means of assessing the efficacy of treatment in myeloma. Mature survival data alone should be used for this purpose.
Insights
Assessing M-protein reduction in multiple myeloma patients showed it
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma treatment efficacy is often assessed by M-protein levels.
- Prognostic factors for multiple myeloma survival require further investigation.
Purpose of the Study:
- To evaluate the prognostic value of percentage M-protein decrement in multiple myeloma patients.
- To determine if M-protein response accurately predicts survival outcomes.
Main Methods:
- Analysis of M-protein levels and survival data in 134 multiple myeloma patients.
- Multivariate analysis using the Cox proportional hazards model incorporating prognostic factors.
Main Results:
- The correlation between M-protein decrement and survival did not reach statistical significance (P=0.069).
- While M-protein decrement, creatinine, and hemoglobin showed correlation with survival, their prognostic power was weak (low R'-statistic).
Conclusions:
- Percentage M-protein decrement is not a reliable indicator for assessing treatment efficacy in multiple myeloma.
- Mature survival data is essential for accurately evaluating treatment effectiveness in multiple myeloma.